Information on how to access Mylotarg™▼ (gemtuzumab ozogamicin) and cytarabine prescribing information and adverse event reporting can be found at the bottom of the page.
MYLOTARG is indicated for combination therapy with daunorubicin (DNR) and cytarabine (AraC) for the treatment of patients age 15 years and above with previously untreated, de novo CD33-positive acute myeloid leukaemia (AML), except acute promyelocytic leukaemia (APL)1
NICE2 and SMC3 have approved MYLOTARG as an option in this indication for patients with favourable, intermediate or unknown cytogenetics and can be initiated whilst awaiting cytogenetic or molecular testing results
View EFS data
From Day 1
Across patient subgroups
*NICE and SMC advise use in patients with a favourable, intermediate or unknown cytogenetic profile1,2
Click below for dosing, schedule and administration information including Pharmacy and Dosing Guides available to download
View Dosing and Administration Information
View EFS data
Watch Professor Robert Hills discuss the key clinical data from the pivotal ALFA study
Learn more on Efficacy & Safety
Watch Dr Eleni Tholouli discuss the NICE approval for MYLOTARG and efficacy data using the ALFA schedule
Learn more on Efficacy
These pages are not intended for patients or for members of the general public. The healthcare professional web pages contain promotional content.
I confirm that I am a healthcare professional* resident in the United Kingdom.
If you select 'No', you will be redirected to Pfizer.co.uk where you will be able to access reference information on Pfizer's prescription medicines.
*The ABPI Code definition for healthcare professional is members of the medical, dental, pharmacy and nursing professionals and any other persons who in the course of their professional activities may administer, prescribe, purchase, recommend or supply a medicine.
PP-PFE-GBR-2688. December 2020